[1] |
Pancreatic Cancer Committee of Chinese Anti-Cancer Association. Comprehensive guidelines for the diagnosis and treatment of pancreatic cancer (2018 version)[J]. J Clin Hepatol, 2018, 34(10): 2109-2120. DOI: 10.3969/j.issn.1001-5256.2018.10.011.
中国抗癌协会胰腺癌专业委员会. 胰腺癌综合治疗指南(2018版)[J]. 临床肝胆病杂志, 2018, 34(10): 2109-2120. DOI: 10.3969/j.issn.1001-5256.2018.10.011.
|
[2] |
HE C, WANG J, ZHANG Y, et al. Comparison of combination therapies in the management of locally advanced pancreatic cancer: Induction chemotherapy followed by irreversible electroporation vs radiofrequency ablation[J]. Cancer Med, 2020, 9(13): 4699-4710. DOI: 10.1002/cam4.3119.
|
[3] |
PAIELLA S, de PASTENA M, D'ONOFRIO M, et al. Palliative therapy in pancreatic cancer-interventional treatment with radiofrequency ablation/irreversible electroporation[J]. Transl Gastroenterol Hepatol, 2018, 3: 80. DOI: 10.21037/tgh.2018.10.05.
|
[4] |
HAMMEL P, HUGUET F, van LAETHEM JL, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial[J]. JAMA, 2016, 315(17): 1844-1853. DOI: 10.1001/jama.2016.4324.
|
[5] |
VROOMEN L, PETRE EN, CORNELIS FH, et al. Irreversible electroporation and thermal ablation of tumors in the liver, lung, kidney and bone: What are the differences?[J]. Diagn Interv Imaging, 2017, 98(9): 609-617. DOI: 10.1016/j.diii.2017.07.007.
|
[6] |
VOGEL JA, van VELDHUISEN E, AGNASS P, et al. Time-dependent impact of irreversible electroporation on pancreas, liver, blood vessels and nerves: A systematic review of experimental studies[J]. PLoS One, 2016, 11(11): e0166987. DOI: 10.1371/journal.pone.0166987.
|
[7] |
van ROESSEL S, KASUMOVA GG, VERHEIJ J, et al. International validation of the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging system in patients with resected pancreatic cancer[J]. JAMA Surg, 2018, 153(12): e183617. DOI: 10.1001/jamasurg.2018.3617.
|
[8] |
LENCIONI R, LLOVET JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30(1): 52-60. DOI: 10.1055/s-0030-1247132.
|
[9] |
RUARUS A, VROOMEN L, PUIJK R, et al. Locally advanced pancreatic cancer: A review of local ablative therapies[J]. Cancers (Basel), 2018, 10(1): 16. DOI: 10.3390/cancers10010016.
|
[10] |
Chinese Society of Interventional and Minimally Invasive Therapy, China Medicine Education Association. Expert consensus on image-guided irreversible electroporation ablation for pancreatic cancer (2018 version)[J]. J Clin Hepatol, 2019, 35(2): 299-302. DOI: 10.3969/j.issn.1001-5256.2019.02.011
中国医药教育协会介入微创治疗专业委员会. 影像学引导胰腺癌不可逆电穿孔消融治疗专家共识2018版[J]. 临床肝胆病杂志, 2019, 35(2): 299-302. DOI: 10.3969/j.issn.1001-5256.2019.02.011.
|
[11] |
AL EFISHAT M, WOLFGANG CL, WEISS MJ. Stage Ⅲ pancreatic cancer and the role of irreversible electroporation[J]. BMJ, 2015, 350: h521. DOI: 10.1136/bmj.h521.
|
[12] |
HOU JY, LIU RB, LIU Y, et al. The value of radiofrequency ablation in the special sites of the liver cancer by combining ultrasound guided with CT monitoring[J]. J Clin Radiol, 2012, 31(7): 1014-1017. https://www.cnki.com.cn/Article/CJFDTOTAL-LCFS201207029.htm
侯继野, 刘瑞宝, 刘岩, 等. 超声引导联合CT监视在特殊部位肝癌射频治疗中的应用价值[J]. 临床放射学杂志, 2012, 31(7): 1014-1017. https://www.cnki.com.cn/Article/CJFDTOTAL-LCFS201207029.htm
|
[13] |
BELFIORE MP, RONZA FM, ROMANO F, et al. Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: Our preliminary experience[J]. Int J Surg, 2015, 21(Suppl 1): s34-s39. DOI: 10.1016/j.ijsu.2015.06.049.
|
[14] |
ZHANG Y, SHI J, ZENG J, et al. Percutaneous irreversible electroporation for ablation of locally advanced pancreatic cancer: Experience from a Chinese institution[J]. Pancreas, 2017, 46(2): e12-12e14. DOI: 10.1097/MPA.0000000000000703.
|
[15] |
SCHEFFER HJ, VROOMEN LG, de JONG MC, et al. Ablation of locally advanced pancreatic cancer with percutaneous irreversible electroporation: Results of the Phase Ⅰ/Ⅱ PANFIRE Study[J]. Radiology, 2017, 282(2): 585-597. DOI: 10.1148/radiol.2016152835.
|
[16] |
TONG H, LI XY, CHEN YJ, et al. Complications of nano-knife ablation on locally advanced pancreatic cancer[J]. Chin J Hepatobiliary Surg, 2020, 26(4): 270-271. DOI: 10.3760/cma.j.cn113884-20190923-00312.
仝昊, 李晓勇, 陈艳军, 等. 局部进展期胰腺癌纳米刀消融术后并发症分析[J]. 中华肝胆外科杂志, 2020, 26(4) : 270-271. DOI: 10.3760/cma.j.cn113884-20190923-00312.
|
[17] |
MORIS D, MACHAIRAS N, TSILIMIGRAS DI, et al. Systematic review of surgical and percutaneous irreversible electroporation in the treatment of locally advanced pancreatic cancer[J]. Ann Surg Oncol, 2019, 26(6): 1657-1668. DOI: 10.1245/s10434-019-07261-7.
|
[18] |
MARTIN RC 2nd, KWON D, CHALIKONDA S, et al. Treatment of 200 locally advanced (stage Ⅲ) pancreatic adenocarcinoma patients with irreversible electroporation: Safety and efficacy[J]. Ann Surg, 2015, 262(3): 486-494; discussion 492-494. DOI: 10.1097/SLA.0000000000001441.
|
[19] |
YANG PC, HUANG KW, PUA U, et al. Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer-A multi-institutional clinical study in Asia[J]. Eur J Surg Oncol, 2020, 46(5): 811-817. DOI: 10.1016/j.ejso.2019.12.006.
|
[1] | Di WU, Dahua DAI, Wenmei LIANG, Bao FU, Xiaoyun FU. Clinical features of acute pancreatitis in pregnancy and related risk factors[J]. Journal of Clinical Hepatology, 2024, 40(5): 1009-1015. doi: 10.12449/JCH240522 |
[2] | Yufeng ZHENG, Xulei ZHANG, Yuhang WENG, Yongfeng YANG. Etiological spectrum and clinical features of patients with unexplained liver disease manifesting as isolated jaundice: An analysis of 91 cases[J]. Journal of Clinical Hepatology, 2023, 39(5): 1105-1109. doi: 10.3969/j.issn.1001-5256.2023.05.016 |
[3] | Chengsi ZHAO, Weijie YAO, Peng YUAN, Zuozheng WANG. Time distribution of risk factors for secondary pancreatic infection in acute pancreatitis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1686-1690. doi: 10.3969/j.issn.1001-5256.2022.07.044 |
[4] | Ruihua ZHANG, Tingting QIN, Yueming SHAO, Yu ZHANG, Yang WANG, Xiaoyu WEN. Jaundice and portal hypertension caused by hepatic epithelioid hemangioendothelioma: A case report[J]. Journal of Clinical Hepatology, 2021, 37(7): 1662-1664. doi: 10.3969/j.issn.1001-5256.2021.07.036 |
[5] | Si XIE, Ming YANG, Yuan HUANG, Lai WEI. Differential diagnosis and treatment of jaundice after comprehensive treatment of advanced primary liver cancer: A case report[J]. Journal of Clinical Hepatology, 2021, 37(2): 400-402. doi: 10.3969/j.issn.1001-5256.2021.02.030 |
[6] | Wang CaiBin, Su Yang. Risk factors for posthepatectomy liver failure and related prevention and treatment methods[J]. Journal of Clinical Hepatology, 2020, 36(9): 2119-2124. doi: 10.3969/j.issn.1001-5256.2020.09.048 |
[7] | Cao Yuan, Yao GuoXiang, Shi YiHai. An excerpt of international consensus guidelines for risk factors in chronic pancreatitis (2020)[J]. Journal of Clinical Hepatology, 2020, 36(8): 1720-1722. doi: 10.3969/j.issn.1001-5256.2020.08.008 |
[8] | Lei Yu, Li JiaJia, Liu RongAn, Ceng Fan, Li GuiSen, Lan YunPing. Clinical features of patients with sepsis-induced cholestatic jaundice and risk factors for death[J]. Journal of Clinical Hepatology, 2020, 36(5): 1065-1071. doi: 10.3969/j.issn.1001-5256.2020.05.023 |
[9] | Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044 |
[10] | Ren DanDan, Liu Na, Zhou LuLu, Zhang Nan, Li ChunXia, Dong Bing, Xu GuangHua. Risk factors for hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1634-1638. doi: 10.3969/j.issn.1001-5256.2020.07.041 |
[11] | Luo XiaoKe, Li XiaoLing, Yang LiMing, Wang XiaoHong. Efficacy of magnesium isoglycyrrhizinate in treatment of hepatitis E with severe jaundice[J]. Journal of Clinical Hepatology, 2014, 30(6): 537-539. doi: 10.3969/j.issn.1001-5256.2014.06.014 |
[12] | Yu Zheng, Jia JiDong. Risk factors, diagnostic criteria, and drug discontinuation criteria for drug- induced liver injury[J]. Journal of Clinical Hepatology, 2013, 29(9): 674-677. doi: 10.3969/j.issn.1001-5256.2013.09.010 |
[13] | Bao XuLi, Tian Zhou, Chen QingFeng, Li Li, Zhang Lei, Lu: Jun. One case of primary hepatic amyloidosis characterized by jaundice[J]. Journal of Clinical Hepatology, 2013, 29(12): 943-944. doi: 10.3969/j.issn.1001-5256.2013.12.018 |
[14] | Wu XiaoQing, Wan Hong. Causes of liver failure and impact analysis of prognostic risk factors[J]. Journal of Clinical Hepatology, 2013, 29(4): 294-296+304. |
[15] | Chen Qian, Wen XiaoYu, Pan Yu. Jaundice due to hepatic syphilis: A case report[J]. Journal of Clinical Hepatology, 2013, 29(4): 303-304. |
[16] | Yang ZongGuo, Chen XiaoRong, Lu YunFei, Liu Cheng. Decotion in chronic hepatitis B patients (damp-heat blood stasis syndrome) with low-grade jaundice[J]. Journal of Clinical Hepatology, 2012, 28(10): 771-774+784. |
[17] | Shi HaiDong. Clinical observation of alprostadil injection in the treatment of liver cirrhosis with jaundice[J]. Journal of Clinical Hepatology, 2011, 27(9): 962-964. |
[18] | Dou WeiJia, Zhou Lin, Wu KaiChun. Risk factors of chronic pancreatitis[J]. Journal of Clinical Hepatology, 2011, 27(11): 1180-1183. |
[19] | Wang Hong, Wang YingMin, Zhang Bo. Prospective analysis of risk factors for the occurrence of hepatocellular carcinoma in patients with post-hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2007, 23(1): 34-35. |
[20] | Wang Hong. Risk factors for patients with cirrhosis developed renal dysfunction[J]. Journal of Clinical Hepatology, 2004, 20(2): 101-102. |